Antibody-Drug Conjugates Take Center Stage in Platinum-Resistant Ovarian Cancer
Platinum-resistant ovarian cancer remains one of the most difficult settings in gynecologic oncology, largely because the disease has already escaped the treatment backbone that once defined its care. In this review, antibody-drug conjugates such as mirvetuximab soravtansine and trastuzumab deruxtecan emerge as a major therapeutic advance for selected patients when platinum-based chemotherapy is no longer a viable option.
The biological logic is straightforward. ADCs use a surface antigen to ferry a highly potent payload into cancer cells, allowing treatment to concentrate cytotoxicity where the target is present while limiting exposure elsewhere. In ovarian cancer, that targeting strategy matters because the disease is frequently heterogeneous and heavily pretreated, two features that blunt the effect of conventional chemotherapy and leave few reliable options once platinum resistance develops.
FRα and HER2 as Actionable Targets
The review places particular emphasis on two agents with clinically meaningful activity in biomarker-defined populations: mirvetuximab soravtansine, which targets FRα, and trastuzumab deruxtecan, which targets HER2. Both examples illustrate a larger shift in ovarian cancer therapy away from one-size-fits-all cytotoxic treatment and toward target selection based on tumor biology.
FRα expression has become especially important in platinum-resistant disease because it gives clinicians a way to identify patients most likely to benefit from a targeted payload delivery system. HER2-directed therapy expands that concept into a different molecular niche, reinforcing the idea that ovarian cancer cannot be treated as a single entity once resistance has emerged. The practical consequence is a deeper dependence on tumor profiling, not as an academic exercise, but as the gateway to treatment options that can still produce meaningful activity.
ADCs are not free of resistance themselves. Tumors can lower or lose the target antigen, reducing drug delivery at the cell surface, or adapt to the payload after repeated exposure. Those resistance pathways are not abstract laboratory observations; they are the reason a response to an ADC may be temporary even when the initial signal is strong. Once the tumor learns to evade either the target or the payload, the same precision mechanism that made the drug attractive can also become its weak point.
Why Resistance to ADCs Becomes Inevitable
Resistance in this setting develops through more than one route. Target antigen downregulation can make a previously sensitive tumor less visible to the drug, while payload resistance can blunt the killing effect even when the ADC still reaches the malignant cell. Together, these mechanisms explain why durable disease control remains difficult in many patients with platinum-resistant ovarian cancer.
This is where the translational agenda becomes clinically relevant. Predictive biomarkers are needed not only to decide who should receive an ADC, but also to determine when the biology of a tumor is shifting away from that approach. Without better biomarker guidance, treatment sequencing risks becoming reactive rather than strategic, especially as multiple newer options begin to compete for the same line of therapy.
Combination Strategies Aim to Push Beyond Single-Agent Limits
The review also moves beyond ADCs alone and examines broader systemic approaches that have produced survival gains in platinum-resistant ovarian cancer, including in biomarker-unselected populations. One example is the addition of the glucocorticoid receptor antagonist relacorilant to nab-paclitaxel. Another is the use of immune-chemotherapy combinations such as pembrolizumab plus paclitaxel, with or without bevacizumab.
Those combinations matter because platinum-resistant disease often reflects a biologically adaptive tumor state rather than a single actionable mutation. By pairing agents with different mechanisms, clinicians may be able to disrupt several survival pathways at once: microtubule injury from chemotherapy, vascular effects from antiangiogenic therapy, glucocorticoid pathway suppression, and immune activation. The rationale is not simply additive toxicity avoidance or incremental efficacy. It is an attempt to outmaneuver a tumor that has already survived one of oncology’s most important cytotoxic classes.
A single pathway rarely stays dominant for long in this disease.
Replication Stress and Immune Platforms Enter the Picture
Future development is leaning toward combinations designed to overcome the specific escape routes that limit ADC activity. The review points to pairing ADCs with replication stress inhibitors such as ATR inhibitors and WEE1 inhibitors, both of which exploit vulnerabilities in damaged tumor DNA handling and cell-cycle checkpoint control. In a tumor under pressure from a cytotoxic payload, blocking repair and checkpoint escape could theoretically deepen the injury and reduce the chance of recovery.
The same logic extends to next-generation immuno-oncology platforms, including bispecifics, T-cell engagers, and cancer vaccines. These strategies are being considered because ovarian cancer has not been easily conquered by immune therapy alone, especially outside carefully selected settings. Yet when immune engagement is layered onto targeted drug delivery or checkpoint disruption, the therapeutic opportunity changes. A tumor that has already been stressed by an ADC may become more vulnerable to immune-mediated clearance, provided the biology is right and the immune microenvironment can be coaxed into action.
Biomarker-Driven Sequencing Will Shape the Next Phase
The review closes by placing dynamic biomarkers and quantitative tools at the center of future treatment design. That emphasis is important because the next challenge in ovarian cancer is not simply finding active drugs, but deciding when to use them, in what order, and for which tumor biology. Dynamic testing could help define whether a lesion remains target-positive, whether resistance has emerged, and whether a patient should stay on a targeted path or move to a different mechanism before the disease escapes again.
This is a disease in which sequence can matter as much as selection. As more ADCs, immunotherapy combinations, and replication stress inhibitors enter the field, the major clinical question becomes how to match biology to therapy across the arc of resistance. The review makes clear that platinum-resistant ovarian cancer is no longer limited to fallback chemotherapy alone, but it also shows how fragile progress remains when resistance pathways are not fully understood.
The next phase of progress will depend on integrating target expression, resistance biology, and rational combinations into a treatment plan that can adapt as quickly as the tumor does. Until then, the central challenge remains the same: finding a way to make targeted delivery last longer than the cancer’s ability to evade it.